Christophe Bourdon, Leo Pharma CEO
February 26, 2025 03:00 AM ESTUpdated 08:27 AM
Pharma

Leo Phar­ma says its years­long makeover is about to pay off

Ayisha Sharma

News Reporter

For the first time since 2018, der­ma­tol­ogy-fo­cused Leo Phar­ma projects that it could turn a prof­it this year.

Its Wednes­day guid­ance comes on the heels …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

BioN­Tech de­tails promis­ing mid-stage da­ta for its PD-L1xVEGF in ag­gres­sive lung can­cer

On the heels of staff cuts, CRISPR Ther­a­peu­tics COO de­parts; Changes ga­lore at Bi­cy­cle

No­vo inks sec­ond obe­si­ty deal of the week, with Lex­i­con oral drug part­ner­ship worth up to $1B

Eu­ro­pean reg­u­la­tor re­jects Lil­ly's Alzheimer’s drug over po­ten­tial­ly fa­tal side ef­fects

Be­fore Alu­mis went pub­lic via IPO, it tried do­ing a re­verse merg­er with Ace­lyrin

Mer­ck KGaA pays Ab­bisko $85M for full com­mer­cial rights to be­nign tu­mor drug

A service from the Financial Times